Eli Lilly has launched higher-dose versions of its weight loss drug, Zepbound, in single-dose vials at reduced prices to make the medication more accessible to uninsured patients, including those on Medicare.
The new pricing options are available through LillyDirect, the company’s direct-to-consumer platform.
The 7.5 milligram and 10 milligram vials are offered at a discounted rate of $499 per month for first-time prescriptions and refills within 45 days. After this period, the vials will cost $599 and $699, respectively. This new approach aims to help more patients access the treatment, especially those who do not have insurance coverage for weight loss medications.
Eli Lilly is also lowering the price of its lower-dose vials of Zepbound, with the 2.5 milligram vial now priced at $349 and the 5 milligram vial at $499 per month. The company intends to address the growing demand for Zepbound while discouraging the use of unapproved, compounded alternatives, which have raised safety concerns.
